Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.

Jazirehi AR, Economou JS

Open source

DOI
10.1158/1535-7163.mct-11-0814
Published
2012 Jun
Container
Molecular cancer therapeutics
Publisher
Not recorded
Open access
yes

Credibility signals

serious concern Score 10/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1158/1535-7163.mct-11-0814,
  title = {Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.},
  author = {Jazirehi AR and Economou JS},
  year = {2012},
  journal = {Molecular cancer therapeutics},
  doi = {10.1158/1535-7163.mct-11-0814},
  url = {https://doi.org/10.1158/1535-7163.mct-11-0814}
}

RIS

TY  - JOUR
TI  - Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.
AU  - Jazirehi AR
AU  - Economou JS
PY  - 2012
JO  - Molecular cancer therapeutics
DO  - 10.1158/1535-7163.mct-11-0814
UR  - https://doi.org/10.1158/1535-7163.mct-11-0814
ER  - 

APA

AR, J., & JS, E. (2012). Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLs.. Molecular cancer therapeutics. https://doi.org/10.1158/1535-7163.mct-11-0814

Source records